ABSTRACT
Since the first description of prion diseases, great effort has been made toward comprehending this new paradigm in biology. Despite large advances in the field, many questions remain unanswered, especially concerning the conversion of PrP C into PrP Sc . How this conformational transition evolves is a crucial problem that must be solved in order to attain further progress in therapeutics and prevention. Recent developments have indicated the requirement for partners of the prion protein in triggering the conversion. In the present review, we will explore the interaction of PrP with some of its most intriguing partners, such as sulfated glycans and nucleic acids. These molecules seem to play a dual role in prion biology and could be fundamental to explaining how prion diseases arise, as well as in the development of effective therapeutic approaches.
INTRODUCTION

Prion Diseases
According to the World Health Organization (WHO) website, between 1986 and 2002, almost 200,000 cases of bovine spongiform encephalopathy (BSE) were registered in Great Britain (WHO official website: www.who.int). The "mad cow disease" epidemic caused serious damage to the European economy at the end of the 1980s and the beginning of the 1990s and led to the death of thousands of cattle across Europe. Since the first description of variant Creutzfeldt-Jakob disease (vCJD) in humans in 1995, over 200 cases have been recorded in England, France, Ireland, Italy, and the USA.
Transmissible Spongiform Encephalopathies (TSEs) belong to a group of conformationally misfolding neurodegenerative disorders. They are rare, fatal, affect mammals (including humans), and are characterized, in general, by the loss of motor control, paralysis, and dementia (1). In addition to the hereditary and sporadic forms of prion disease, the group also possesses an infectious nature as well. All TSEs are progressive, fatal and incurable (1). The TSEs that affect humans are: Creutzfeldt-Jakob disease (CJD), the Gerstmann-Sträussler-Scheinker syndrome (GSS), Fatal Familial Insomnia (FFI) and the previously eradicated kuru.
The first description of a TSE dates back to the mid-eighteenth century, when the first cases of scrapie (the prion disease that affects sheep) compromised the expansion of the textile industry during the Industrial Revolution (2). At the beginning of the twentieth century, the first cases of Creutzfeldt-Jakob disease were reported in humans (3, 4). In the mid-twentieth century, kuru was identified as a TSE in Papua New Guinea, and resulted from contamination by the practice of ritualistic cannibalism, killing a large number of the local aborigine population (5). Subsequently, Alper and collaborators demonstrated that the infectious agent related to TSEs was highly resistant to treatments that affect nucleic acids, such as ionizing radiation and ultraviolet light (6), suggesting that a protein alone could infect and replicate in the absence of nucleic acids (7). In the 1980s, the neuroscientist Stanley Prusiner characterized the infectious agent and the concept of the prion: proteinaceous infectious particle (8, 9).
All TSEs, including scrapie in sheep and BSE in cow, have been described as single infectious agents that are isoforms of a constitutive protein known as the prion protein (PrP) (2). There are two main players involved in prion disease. The first is the cellular prion protein (PrP C ), an isoform that occurs naturally in cells of the host body (10). The second is a conformational variant of the first, which is involved in transmission of the disease, such as the prion scrapie (PrP Sc ) (11).
Cellular prion protein (PrP
C )
PrP C (or PrP-sen, for protease-sensitive) is a constitutive and highly conserved protein among mammals (1). It is normally found in the membrane of mammalian cells in many tissues, such as kidney and skeletal muscle (2). PrP c is found in particular abundance in the central nervous system (12), and also in lymphocytes and lymphoid organs (13) . This protein is encoded by the PRNP gene contained in chromosome 20 in humans, and present only in one copy (12). Mature PrP contains 209 amino acid residues, two preserved glycosylation sites, and is anchored to the outer cell membrane through a glycosyl phosphatidyl inositol (GPI) anchor (1, 14).
The mouse prion protein is synthesized in the endoplasmic reticulum as a protein with 254 amino acid residues. The first 22 amino acids in the amino-terminal region localize the protein to the membrane. Post-translational processing attaches the C-terminal region of the PrP GPI anchor, fixing it to the outer portion of the cell membrane (1). There are two N-glycosylation sites present in asparagine residues 181 and 197 (in human PrP), to which are added a variety of sugar species (15, 16) . PrP possesses a sequence of eight amino acid residues (PHGGGWGQ) in its aminoterminal region between residues 50 and 90 that are flanked by basic and hydrophobic segments (residues 23-50 and 99-120, respectively) (17, 18) . This octapeptide region is highly conserved and contains four repetitions of these eight amino acids that function to bind copper (18, 19) .
The tertiary structures of recombinant prion proteins (rPrP C ) from different species were determined by nuclear magnetic resonance (17, (20) (21) (22) . The human PrP structure reveals the presence of a globular domain (residues 125 to 228) and a highly disordered aminoterminal domain (23) . The globular domain contains three alpha-helices (residues 144-154; 173-194 and 200-228 ) and a small beta-sheet formed by two beta-strands comprising residues 128 to 131 and 161 to 164 (23) (Figure 1) . The Prnp gene was identified in the 1980s. It is located on chromosome 2 in mice and 20 in humans (see (24) for review). The knockout mouse for this gene was generated in 1992 (25) . Today, almost three decades after the identification of the Prnp gene and 16 years after construction of the first prion protein knockout animal, little is known about its physiological function. Over the years, many functions have been assigned to PrP C , including immune regulation, signal transduction, copper metabolism, nucleic acid processing, synaptic transmission, protection, and induction of apoptosis (26) (27) (28) .
Despite all efforts to elucidate the physiological role of PrP C , a specific function has not been firmly established. Many biological partners for PrP have been identified that could be involved in its function. Based on the currently available data, it is suggested that the presence of the GPI anchor indicates the requirement for PrP to bind a transmembrane protein to transfer an extracellular signal to the intracellular space, indicating PrP may function as an accessory protein (27) .
The most studied ligand of the prion protein is copper (19) , which interacts with PrP through its aminoterminal domain, suggesting a function in copper metabolism (28) . Some studies have suggested that PrP C is able to bind extracellular matrix macromolecules, such as laminin (29, 30) and the laminin receptor (31) . PrP has also been shown to interact with and modulate the activation of plasminogen (32) . Other ligands for cellular PrP have been reported: the chaperones Hsp60 and GroEL; STI1 (stressinducible protein I); nNOS (Neural nitric oxide synthase); alpha-tubulin (33-36); and nucleic acids (37, 38).
The prion scrapie (PrP
Sc
) and the conversion reaction PrP Sc is the isoform of PrP C associated with prion diseases, and is enriched in beta-sheet structures, as measured by Fourier transform infrared spectroscopy (FTIR). PrP Sc presents itself as an insoluble protein that has a tendency to aggregate, and is partially resistant to digestion by proteases. For this reason it is also called PrPres (39). The protease resistant core forms amyloid fibrils and amorphous aggregates comprising residues 90 to 231 (40). Because of the tendency to form aggregates, determination of the three-dimensional structure of PrP Sc by high-resolution techniques, such as X-ray crystallography and nuclear magnetic resonance, has proven to be a challenge. However, molecular modeling studies suggest that the formation of PrP Sc involves the refolding of residues 90 to 140 into beta-sheets (41). The single disulfide bond, which links the helices on the Cterminal region, would remain intact since this bridge is necessary for the formation of PrP Sc (42). A recent model included the flexible region of the prion protein (residues 89 to 175), suggesting that this domain could also fold into beta-sheets (43).
The "protein-only hypothesis" was first outlined by Griffith (7) and developed by Stanley Prusiner (1). According to this theory, the prion protein is the main agent responsible for the outbreak of TSEs. The discovery that PrP knockout mice are resistant to infection by prions (25, 44 ) is one of the most solid foundations that support this theory. Changes in protein secondary structure from an alpha-helical-rich conformation to a higher beta-sheet content account for the physical-chemical differences between (Figure 2 ).
Several biophysical approaches have been applied to characterize the thermodynamic properties of the alpha-helical PrP C and beta-sheet species (53-55). The freeenergy diagram depicted in Figure 2 highlights a model in which the cellular isoform is in a metastable conformation. High-pressure FTIR and pressure perturbation calorimetry studies have demonstrated that the cellular PrP isoform is more hydrated and has a larger solvent-accessible surface area than aggregated a-rPrP obtained by thermal treatment (55-57). The role of hydration in the folding stability and amyloidogenicity of PrP has been corroborated by computer modeling and molecular dynamics (58, 59). As represented in Figure 2 , binding of a cofactor or a catalytic effector (such as nucleic acid) would lead to a decrease in solvent-accessible surface area and a decrease in the level of hydration. The finding that PrP C is highly hydrated is consistent with the observation that the protein has a long, disordered segment (the N-domain), and the globular Cdomain is highly flexible and not well-packed. Upon binding to biological targets, disordered segments can fold and become less hydrated. This could occur with PrP C when it binds a partner such as a glycosaminoglycan or nucleic acid. Alternatively, this could also happen by protein-protein interactions with assembling oligomers or amyloid fibrils. Below, we focus our review on the nucleic acid-and glycosaminoglycan-binding properties of the prion protein and try to clarify the importance of these ubiquitous macromolecules in prion biology, as well as in the occurrence of transmissible spongiform encephalopathies.
ARE COFACTORS NEEDED FOR PRION INFECTIVITY?
Since the proposal of the protein-only hypothesis, scientists have had little success generating infectious prion particles from recombinant prion protein (60, 61) . Even the generation of detergent insoluble aggregates and protease resistant prion particles, which possess classical characteristics of PrP Sc , failed to produce infectivity in animals (62) . The lack of infectivity indicated that something was missing in the generation of infectious prion particles in vitro.
Through the protein-misfolding cyclic amplification (PMCA) technique first described by Saborio and collaborators in 2001, it was shown that a mixture of crude homogenates from normal and scrapie brain resulted in a 6-fold amplification of PrP-res (63, 64) . However, it was necessary to use a 50-fold excess of PrP-res template to drive conversion in a cell-free system containing only purified proteins (45). These results indicate that other factors are required for efficient conversion and that brain homogenates must contain such adjuvants.
Legname and coworkers (65) published a paper that claimed to contain the definitive proof for the proteinonly hypothesis. This group managed to induce the disease in transgenic animals by inoculating them with a recombinant prion protein (residues 89 to 230) in its fibrillar beta-sheet-rich form. The disease was induced in transgenic animals overexpressing the prion fragment (PrP 89-230). However, animals bearing many copies of the prion protein developed the disease later on and, in some cases, presented a sub-clinical form of scrapie. Therefore, it seems that the injected material only accelerated the process in transgenic animals expressing excess PrP.
Studies with transgenic animals also suggest that conversion of PrP C into PrP Sc could be assisted by another biological macromolecule (49). This observation could explain the species barrier in prion diseases (49). The adjuvant could be a binding cofactor or even a specific posttranslational modifier (49, 66).
It is currently well-accepted that an unknown factor is involved in prion pathology (38, 48, 49, 67) . This molecule would function by lowering the free energy barrier between PrP C and PrP Sc and triggering conversion (53, 68). A great number of biological macromolecules have emerged as candidates for conversion catalysts: cellular adhesion molecules, extracellular matrix molecules, glycosaminoglycans, and nucleic acids. All of these molecules have been reported to interact with PrP and trigger structural conversion from an alpha-helical-rich structure to a beta-sheet-rich form (38, 48, 50, 69, 70) . Throughout this review, we will focus mainly on two prion protein ligands: the glycosaminoglycans and nucleic acids.
INTERACTION WITH SULFATED POLYSACCHARIDES
Proteoglycans (PG) are glycoproteins consisting of a core protein covalently linked to one or more glycosaminoglycan chains. Glycosaminoglycans (GAGs) are linear polysaccharides comprised of a disaccharide repeat unit of a hexuronic acid linked to a hexosamine that is mainly modified by N-deacetylase and Nsulfotransferases. Sulfated polysaccharides have long been shown to interact with several proteins. They play important roles in the regulation of many physiological processes, including cell-cell and cell-matrix interactions, cell growth and proliferation, and viral infection (for review see (71)). GAGs have been implicated in many conformational diseases and have been detected in different types of amyloid deposits since the 19 th century (72-76). In addition, the importance of these molecules is not only restricted to spatial deposition, but also to temporal appearance (77) and the induction of conformational changes (78) in amyloidogenesis.
Numerous evidences reveal the direct binding of GAGs to PrP C in soluble form and at the cell surface (50, 79-81). The decrease in cellular heparan sulfate content leads to a strong reduction in PrP Sc formation and incorporation in cells to regulate the metabolism of prions (82, 83) . These observations indicate that the interaction of HS proteoglycans and PrP C /PrP Sc is essential for the pathogenesis of prion diseases.
The paradoxical effect of sulfated glycans.
GAGs, mostly heparan sulfate (HS), have been the subject of many prion disease studies. Snow and collaborators were the first to show the presence of heparan sulfate in amyloid plaques in prion diseases like Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, and scrapie (76, 84) . Since then, efforts have focused on the function of these carbohydrates in transmissible spongiform encephalopathy pathogenesis.
After the identification of GAGs as considerable amyloid aggregate components, some studies showed that sulfated polysaccharides can inhibit the accumulation of PrP-res in cells infected with scrapie, and can bind PrP C (50, 85). One explanation for this finding is that exogenous sulfated compounds inhibit PrP Sc production by decreasing the amount of plasma membrane PrP C . Since no alteration in the synthesis or degradation of PrP C was observed, the observed effect may be due to an increase in the rate of endocytosis induced by these compounds (86) . Another work demonstrated that sulfated GAGs could inhibit the polymerization of synthetic prion peptides into amyloid fibrils (87) . It is postulated that the interaction of PrP (PrP C and/or PrP Sc ) with endogenous GAGs could be necessary for PrP Sc propagation, and that exogenous GAGs act as inhibitors that block the interaction of PrP with endogenous PG (78) . According to this hypothesis, endogenous GAGs at the cell membrane possess characteristics that are necessary to facilitate PrP Sc formation/propagation and differ from exogenous molecules that do not cause this effect.
Wong and collaborators (78) used a cell-free conversion assay to show that sulfated glycans induce conformational changes in PrP-sen and stimulate the conversion of PrP-sen to a PrP-res isoform, which probably acts as a cofactor in the pathogenic process. Exogenous GAGs have been shown to reconstitute the formation of PrP Sc in cells possessing strongly reduced membraneassociated GAGs (82) . Furthermore, heparan sulfate proteoglycans (HSPG) stimulated PrP-res amplification in vitro (88) , and heparin enhanced the aggregation of a prion protein fragment (PrP ) and induced the formation of amyloid aggregates that are toxic to neuronal cells (89, 90) . The ability to stimulate PrP conversion reveals the paradoxical effect of these sulfated glycans.
Function of the PrP C :GAG interaction
PrP C is mainly located on the cell surface where it interacts with cell surface proteoglycans and the extracellular matrix. Heparan sulfate proteoglycans (HSPG) on the cell membrane are mainly syndecans (Sdc) or glypicans (Gpc). The ability to bind GAGs may be involved not only in the pathogenesis of prions, but also in the normal function of PrP and HS.
Although PrP C is a GPI-anchored membrane protein with no cytoplasmic domain, it appears to be involved in neurite outgrowth and neuronal survival through signal transduction pathways, including the nonreceptor Src-related family member p59 (Fyn), PI3 kinase/Akt, cAMP-dependent protein kinase A, and MAP kinase. (91) . N-syndecans are transmembrane cell surface proteoglycans that interact with Src family kinases and mediate neurite outgrowth (92) . Therefore, the effect of PrP on promoting neurite outgrowth and neuronal survival may be modulated by its interaction with HSPG.
GAGs also mediate the interaction of prion protein with other molecules, such as the 37-kDa/67-kDa laminin receptor (LRP/LR) (93, 94) . Like heparan sulfate, LRP/LR is another prion ligand that is believed to be a cell membrane receptor for PrP C and PrP Sc (31, 95) . Not only does heparin function as a cofactor to mediate plasminogen activity through PrP C stimulation of tissue-type plasminogen activator (t-PA), but it may also influence cellular proteolysis (96) .
Glypicans, which include PrP C , are GPI-anchored proteins present in lipid rafts (for review see (97)). Gpc-1 recycling involves internalization via the caveolae pathway and degradation in lysosomes. This process leads to removal and either enzymatic degradation of the HS sulfate chains by heparanase or non-enzymatic degradation by (Cu(II)-⁄Zn(II)-dependent, nitric oxide (NO)-catalyzed deaminative cleavage. These processes generate products, such as anhydromannose oligosaccharides, that interact with oxidized proteins and the proteasome to participate in the clearance of misfolded proteins (98) . Recycling Gpc-1 is also crucial for the uptake of polyamines, which are important molecules for cell growth and survival (99) . Gpc-1 possesses conserved cysteine residues in the central domain that are Snitrosylated in a Cu(II)-Cu(I)-dependent redox cycle during endocytosis (100). PrP C is known to bind copper at the octapeptide repeat region of its N-terminal domain, and has been related to copper metabolism and oxidative stress (for review, see (101) 
Heparin/Heparan sulfate binding sites
The presence of sulfur and carboxyl groups makes GAGs negatively charged molecules. Interactions with other proteins are mainly ionic and depend on the presence of basic amino acids throughout the protein sequence. Although the interaction might look random, GAGs have specific requirements for defined sequences. Cardin and Weintraub (105) were the first to show the presence of defined motifs in heparin-binding domains of four proteins (105) . They characterized two consensus sequences, XBBXBX and XBBBXXBX, where B is a basic residue and X is any other amino acid (105). Sobel and collaborators also proposed a third consensus sequence, XBBBXXBBBXXBBX (106) . These motifs are not always found as binding regions; therefore, other spatial patterns for heparin binding must exist (107, 108) .
Lysine and arginine are basic amino acids that show greatest affinity for sulfated glycans, with arginine exhibiting 2.5 times greater affinity (109) . Histidine residues are also important for heparin interactions, with some proteins demonstrating a strong pH and cation binding dependence (110) (111) (112) (113) .
The prion protein's conserved octapeptide repeat region at the N-terminus has a consensus sequence of PHGGGWGQ that binds Cu(II) (114) . The presence of extra octapeptide repeats is associated with prion disease (115, 116) . Although this region is not a heparin-binding motif, evidence indicates that it can bind heparin. The interaction could be mediated by divalent ions bound to protonated His side chains (117, 118) . Additionally, the interaction between LRP/LR and PrP is thought to be dependent on an HSPG bridge that interacts with the octarepeat region (93) . A synthetic peptide of amino acids 53-93 was shown to interact with heparin/HS, as demonstrated by biosensor analysis (80) .
Aside from the octapeptide region, Warner and collaborators (80) The amino acid sequence and saccharide domains of the polysaccharide chain are important for the protein:GAG interaction. The uronic acid residues of Heparin/HS can be 2-O-sulfated or unsubstituted. Glucosamine can be 6-O-sulfated, N-acetylated, unsubstituted, or N-sulfated. An N-unsubstituted GlcN and a 3-O-sulfate group (an unusual modification encountered in GlcN) are involved in the binding of HS to herpes simplex gD (122) . The N-sulfated GlcN, IdoA, 6-O-sulfate, and 3-O-sulfate groups are required for antithrombin binding (123) . Both the size and the degree of sulfate content in heparan mimetics are important for their ability to inhibit PrP endocytosis (124) . Not only is sulfate density important for the interaction, but it also affects the properties of the glycan backbone. Chondroitin sulfate and kappa-carrageenan possess similar sulfate densities, but they do not have the same effect (85) . Using competition assays, Warner and collaborators showed that removal of the 2-O-sulfate group reduced the capacity to compete for interaction with PrP C -heparin. Removal of the 6-O-sulfate group had only a minor effect. Hence, the 2-O-sulfates of heparin play an important role in substrate recognition (80).
PRP INTERACTION WITH NUCLEIC ACIDS
Nucleic acid molecules, both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), form a peculiar group of PrP ligands. Due to the "protein-only" hypothesis, these molecules were excluded from prion biology for decades (1, 9), but they are now being considered for several new roles: instead of carrying genetic information, DNA and RNA molecules can participate in prion diseases as adjuvants in the conversion of PrP C into PrP Sc , and they may generate toxic species (38, 48, 50, 69, 125, 126) . On the other hand, they have been shown to prevent PrP aggregation and accumulation in cultured cells (127, 128) . The participation of nucleic acids as prion protein cofactors was first considered by Weissmann in 1991 when he raised the idea that another molecule, such as a nucleic acid, could play a crucial role in the propagation of prion proteins (10). Nucleic acid binding of recombinant PrP to DNA was described by Nandi & Leclerc (129) . In 2001, we provided the first experimental evidence for the catalytic participation of a nucleic acid molecule in prion protein conversion (48).
Some research groups have also proposed the use of modified NA molecules as prototypes for prion diagnosis (130, 131) . Another interesting feature of the interplay between prions and NAs is that the former might participate in nucleic acid processing as an NA chaperone (38, [132] [133] [134] . DNA and RNA molecules present similarities and differences in their effects on prion structure, conversion, aggregation, and propagation (69) . In this section, we focus on PrP interactions with DNA and RNA separately. We will also examine new possibilities and questions raised by the experimental observations of these molecules in prion biology.
Outline: a decade of interesting findings 5.1.1. DNA
The interaction between PrP and DNA molecules has captured the attention of scientists for over a decade, and was first described by P. K. Nandi in 1997. Through fluorescence measurements, he observed that the human PrP-derived peptide PrP could bind a small DNA sequence derived from the papilloma virus with micromolar affinity. This finding was similar to that observed for the retroviral protein p10 (129) .
Two years later, Nandi observed the polymerization of a full-length recombinant murine prion protein (rPrP) in nucleic acid solution (135) . In 2001, our group showed that the same prion protein can bind DNA sequences with high affinity in vitro (48). This interaction can prevent the aggregation of a highly hydrophobic prion peptide derived from the Syrian hamster PrP sequence (ShaPrP ) in a concentration-dependent manner. It can also induce a change in the rPrP conformation, converting it from an alpha-helical-rich structure to an alternative, beta-sheet-rich conformation (48). We proposed that the PrP-nucleic acid complex could act as a catalyst. When the full-length prion protein was added to the rPrP-DNA complex, aggregation did not occur ( Figure 3) ; however, when a large amount of prion β-sheet-rich aggregate was added to a solution containing the DNA complex, aggregation increased drastically (Figure 3) . These results led us to propose that the rPrP-DNA complex catalyzes aggregate formation (48). However, in addition to the PrP-DNA complex, a considerable amount of protein in the scrapie conformation was required. Without excess PrP Following this observation, the interaction of rPrP with synthetic double-stranded DNAs was confirmed to lead to partial unfolding of the protein into an amyloidlike structure. This was characterized by binding to amyloid-specific dyes of Congo red and thioflavin T (136). These amyloid-like structures were also found to be spherical and resistant to proteinase-K (PK) digestion, similar to those in infected brains (137) .
Subsequently, we showed that double-stranded DNA sequences also interact with the rrPrP construct, which lacked most of the unfolded N-terminal domain (PrP∆32-121). This construct contains a deletion of amino acids 32 to 121 (138) . The structural data obtained from Small Angle X-ray Scattering (SAXS) and Nuclear Magnetic Resonance (NMR) measurements showed that rPrP interacts with DNA through the globular domain (Figure 4 ). NMR measurements further identified chemical shift changes in amino acids both in the C and N domains of the protein, suggesting a restructuring of the protein upon DNA binding (138) .
Mangé et al. reported translocation and accumulation of misfolded scrapie-like prions in the nuclei of infected cells, and that this transport was independent of the proteasome machinery. They also reported that the misfolded PrP has the capacity to interact with chromatin (139) . Recently, the interaction of exogenous DNA and recombinant PrP was shown to result in DNA internalization and expression in mammalian cells in the presence of Ca 2+ (140) . Membrane-attached PrP C binds DNA during DNA internalization, but not during DNA expression (140) . Further investigation of DNA interactions with PrP led to the identification of anti-DNA antibodies that were specific to the PrP Sc of diseased human brain tissues. This raised the possibility of using antibodies as markers of prion disease (131) . These data indicate nucleic acids might be physiological ligands of PrP (38). thioaptamers that bind with high affinity to different mammalian prion proteins and short phosphorothioate DNA molecules to decrease the PrP C and PrP Sc content of infected neuroblastoma cells (128, 142) .
RNA
In 1997, Weiss and colleagues isolated RNA aptamers that specifically recognize recombinant prion protein (143) . An interaction was observed for the fulllength Syrian golden hamster protein, but not a construct lacking residues 23 to 90, suggesting that the aminoterminal region is required (143) . Adler and colleagues (144) isolated highly structured RNA molecules that bind recombinant human PrP with high affinity in the presence of bovine serum in vitro. They also observed that this interaction formed oligomers that remained complexed with the RNA, protecting it from ribonuclease A degradation (144) . A few years later, Vasan and coworkers observed that bovine PrP, in the absence of bovine serum, interacted with their RNA aptamers to produce soluble oligomers. These oligomers were sensitive to PK digestion, but were potentially toxic, according to in vitro testing (125) .
Gabus and colleagues demonstrated that PrP possesses the characteristics of RNA-binding chaperones and, similar to the nucleocapsid protein of HIV-1, forms structures similar to nucleocapsid retroviral proteins. Based on their finding, the group suggested that PrP could participate in the metabolism of nucleic acids (133) .
In 2003, several groups investigated the interaction of PrP with RNA in vivo and in vitro to demonstrate that the presence of RNA molecules could stimulate the conversion of PrP C to PrP-res in hamster brain homogenates. They also showed that treatment of these homogenates with RNase could inhibit the conversion (52). In the same year, Rhie and colleagues characterized RNA aptamers that preferentially bind to the infectious form of PrP and inhibit the conversion of the cellular isoform. The aptamer is thought to bind the scrapie form to prevent an interaction between PrP C and PrP Sc (130) . Following this study, other groups presented a series of PrP-binding RNA aptamers (145, 146) .
The in vivo evidence that RNA molecules induce PrP conversion to a PrP Sc -like form was provided by Deleault and coworkers (88, 126) . Through a modified PMCA in vitro reaction, they demonstrated that synthetic RNAs could generate PrP-res formation (88) . This is consistent with our in vitro DNA-binding results suggesting that nucleic acid molecules could be involved in prion conversion (48). In their study, inoculation of commercially available synthetic RNAs, along with purified PrP and copurified lipids caused neurodegeneration in healthy wild type hamsters (126) . Geoghegan and colleagues colocalized hamster PrP extracellular aggregates with RNA molecules, suggesting that RNA molecules incorporate into forming prion aggregates (147) .
Recently, our group characterized the biophysical and structural features of the interaction between recombinant mouse PrP and RNA molecules. We investigated PrP:RNA complex formation through structural changes in PrP during RNA binding. The reagents used include: recombinant full-length rPrP, two constructs lacking different portions of the aminoterminal domain (rPrP∆23-121 and rPrP∆51-90), total RNA extracts from prokaryotic and eukaryotic cells, and two small RNA sequences synthesized in vitro. Our results revealed that the full-length rPrP aggregates upon RNA binding, and immediately loses most of its alpha-helical content. This phenomenon was observed for all RNA samples tested. RNA extracted from neuroblastoma cells (N2aRNA) elicited the most drastic effects. Complex formation with N2aRNA protected both the protein and RNA from degradation with proteinase K and ribonuclease A, respectively (69) . NMR measurements with the synthetic sequence, SAF93 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] , presented a surprising result: after 3 days of incubation, the soluble portion of PrP recovered most of its original fold, but with distinct changes in NMR. The N-terminal deletion constructs revealed that RNA interacts with rPrP at the N-terminal, octapeptide region of the protein between residues 50 and 90. In this study, we also performed viability assays to verify the toxicity of PrP:RNA aggregates. Incubation of cultured neuroblastoma cells with the aggregates revealed that the toxicity of PrP:RNA aggregates was restricted to total RNA extract from N2a cells. Synthetic sequences were not able to induce toxicity, suggesting that an unidentified component present in the total RNA extract of N2a cells is responsible for PrP aggregation and PrP:N2aRNA complex toxicity (69).
New insights on RNA structure and function
For many decades, RNA molecules were classically described as accessories of the cellular machinery involved in DNA translation and transcription (148) . The human genome project showed, however, that only a small portion of our DNA is actually transcribed into protein and the majority does not encode functional sequences. In the past decade, evidence that this portion of our genome is actually largely transcribed has emerged (148, 149) . These versatile transcripts are being revisited, and new functions for them are being proposed. Noncoding RNAs (ncRNA), for example, exercise a variety of important functions in eukaryotic cells, such as posttranslational regulation, cell morphogenesis, and participation in embryo and neural development (for review see (148)). RNA is a flexible molecule, and its structural properties allow it to exercise different roles through a broad range of mechanisms, including cell to cell communication (150) .
As discussed in this review, the interaction of PrP with RNA molecules has been widely reported, and the secondary structure of RNA has been suggested to be important for this interaction (69, 130, (144) (145) (146) . The particular RNA structure necessary for prion binding remains elusive, but the flexibility of such molecules certainly account for these interactions.
DNA vs. RNA: Similarities and differences
All experimental evidence for PrP:NA interactions suggests the partnership of these molecules in vivo. Both DNA and RNA produce misfolded isoforms of PrP. Interestingly, the misfolded PrP isoforms generated by DNA and RNA are not identical. DNA usually produces aggregates with amyloid properties, such as high beta-sheet content and fiber formation (135, 136) . Under some conditions, soluble species are produced (48, 138). Depending on the RNA origin, PrP:RNA complexes can form large aggregates or small oligomers (69, 125) , but they adopt an amorphous morphology (69) . DNA and RNA also bind PrP at different sites: DNA interacts mostly with the C-terminal region, but causes significant changes in the N-terminal domain (138) . Experiments performed with RNA suggest that the RNA binding site is located in the PrP unfolded N-terminal domain; PrP constructs lacking residues 50-90 do not interact with RNA (69, 143) . The toxicity of PrP:NA complexes was observed only for PrP:RNA aggregates (69, 126) .
These findings suggest that a nucleic acid molecule could be involved in prion conversion. Emerging evidence for the extracellular functions of RNA molecules (150) also contribute to the idea that a nucleic acid molecule might be implicated in the generation of PrP Sc . Some groups reported that both DNA and RNA molecules can prevent prion misfolding and propagation in infected cells (48, 128, 131, 141, 142) , and that these molecules could preferentially recognize PrP C or PrP Sc (125, 130) . The experimental evidence raises the possibility for further development of new molecules for TSE diagnosis and therapy.
Binding of NA molecules to PrP can alter the structure of the protein, as well as the structure of the nucleic acid. NA binding can induce modifications in the amino-terminal region of PrP (48, 69, 138) . The interaction with PrP bends DNA molecules and facilitates strand transfer (151) . This property of PrP is consistent with the activity of proteins involved in protein synthesis (151) . These observations, along with the finding that PrP exhibits characteristics of NA-binding proteins (132, 133) , suggest a possible role as an NA chaperone (151, 152) . To confirm this assumption, however, more experimental clues are needed.
NA chaperone and PrP
Sc generation After decades of intense study, spongiform encephalopathies are clinically well-described, but they remain incurable. The spontaneous generation of PrP Sc in sporadic prion diseases, along with the capacity of transmission is still an obscure subject. Despite the At both pHs, the FRET efficiency is greater for the NC-DNA albeit to a smaller extent, and the efficiency is more at pH 7.2 than that at pH 6. Extracted from Bera et al., 2007(155) . significant efforts of the scientific community, the physiological role of PrP C remains unknown (153) . PrP interaction with nucleic acid molecules presents an interesting avenue for understanding prion physiology and the occurrence of TSEs.
Recent studies suggest that the function of PrP C is related to NA metabolism. PrP has been reported to share similarities with viral NA-binding proteins, such as the Ncp7 of HIV1 (133) . Using a methodology to predict DNA interaction sites in proteins, Tjong and coworkers identified 23 residues as possible DNA-binding sites in the murine PrP globular domain (154) . Identification of this binding region is consistent with the findings of our group using chemical shift variation analysis of DNA binding to rPrP via examination of rPrP HSQC spectra (138) (Figure 4) . Anchored PrP C enables DNA translocation to the intracellular space (140) , and recombinant prion proteins can bend small double-stranded DNA molecules and promote DNA expression (140, 155) . The FRET experiments ( Figure 5 ) performed by Nandi's group provide clear-cut evidence that the prion protein modifies the structure of nucleic acids. The observation that the prion protein has a disordered N-terminal domain is consistent with other nucleic acid chaperones (156) and suggests a nucleic acid chaperone function for PrP.
A considerable amount of evidence suggests that nucleic acids can be involved in the conversion of PrPC to PrPSc. Both DNA and RNA can convert recombinant or purified PrP into misfolded isoforms that possess PrPSc characteristics. These studies reported a series of PrP:NA aggregates, some of which induced cell death and neurodegeneration (38, 48, 50, 69, 125, 126, (135) (136) (137) . However, the size, composition, and secondary structure of nucleic acid molecules necessary for binding and converting PrPC to PrPSc are still open for debate. The different effects observed for DNA and RNA molecules indicate that these molecules exercise distinct roles in prion biology. For example: both DNA and RNA can generate aggregated forms of PrP but, until recently, toxicity was only observed in association with PrP:RNA aggregates (69, 126) .
If PrP
C is indeed involved in nucleic acid metabolism, how do nucleic acids convert PrP C into PrP
Sc ? Under what conditions does this interaction become dangerous? The answers to these questions could explain the sporadic incidence of prion disease cases.
PERSPECTIVES IN THERAPY AND DIAGNOSIS
A series of therapeutic strategies have been tested to find an effective treatment against TSEs. However, there is still no efficient approach to preventing disease development and death (for a review on TSE drug therapies, see (157) . A broad variety of compounds have been tested in an attempt to reverse or prevent the formation of PrP Sc , such as Congo Red, amphotericin B, porphyrins, polyamines, and sulfated polyanions (2). These drugs seem to function directly or indirectly in the conversion of PrP C to PrP Sc , and thus prevent the spread of the infectious form. Unfortunately, the compounds tested were not effective in inhibiting the spread of disease when given after the first appearance of symptoms (2). In 2001, Korth and colleagues reported that some phenotiazine and acridine-derived compounds were able to inhibit PrP Sc formation when administered to infected neuroblastoma cells (ScN2a) (158) . Unfortunately, when administered over a long period or at high doses, these drugs caused side effects in humans, such as liver damage (159), and they were not suitable for prion disease treatment. Further work described a screening assay for PrP Sc inhibitors and characterized a group of polyphenols that inhibit the cellfree conversion reaction (160) . In 2004, our group reported that the naphthalene derivative compound 4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate (bis-ANS) can inhibit Syrian hamster PrP peptide ShaPrP(109-149) aggregation (161). This compound is also able to convert rPrP23-231 from its normal alpha-helical form to an alternative, beta-sheet-rich structure. This dual effect was similar to that observed in response to small double-stranded DNA sequences (48). Moreover, binding of bis-ANS to full-length rPrP was reduced by the addition of nanomolar concentrations of oligonucleotides, demonstrating that they compete for the same binding site.
Other groups described the capacity of some NA molecules to reduce PrP Sc formation and to decrease PrP Sc content in infected cells (128, 130, 141, 142) . This interesting property of NA molecules as potential anti-prion compounds opens the possibility of new drugs based on PrP:NA interactions (128, 130, 141, 142) .
Aside from the use of nucleic acids, glycosaminoglycans have long been considered as a candidate for prion therapy. Sulfated glycans were first used for TSE treatment as antiviral drugs when the pathogen was thought to be a virus. Sulfated glycans were able to prolong the incubation time of the disease and prevent symptoms in mice when administered prophylactically (162) (163) (164) (165) . Intraventricular infusion of pentosan polysulfate, an analog of heparin, was reported to increase survival of vCJD patients (70, 166) . Due to the diverse biological functions of heparan sulfate and its involvement in prion diseases, many heparan sulfate mimetics (HMs) are being developed and tested as antiprion drugs. HMs are dextran-based molecules whose hydroxyl groups are substituted with carboxymethyl ether, sulfate esters, or hydrophobic groups. These molecules inhibit PrP Sc accumulation in cell culture without affecting the level of PrP C , and they prolong the survival of scrapieinfected hamsters with no cytopathic or cytostatic effects (167) (168) (169) . HMs could interact with the prion to lower its binding to cellular HS, and increase the length and mediate the degree of sulfation. The introduction of hydrophobicity could positively modulate this effect (124) .
Another developing area in prion diseases is the improvement of new methodologies for TSE diagnosis; PrP:NA interactions could elucidate new possibilities in this field. Some anti-DNA antibodies are able to detect PrP Sc in vivo (131) , and RNA aptamers can bind selectively to PrP C and PrP Sc (145, 146) . The establishment of an effective TSE diagnosis may allow for detection of PrP Sc in pre symptomatic states of prion diseases, and facilitate clearance of PrP aggregates before they become highly toxic. We expect great developments in this field in the years to come.
CONCLUSIONS AND PERSPECTIVES
There is increasing evidence that prions have other additional accomplices that chaperone their activity in converting the normal, cellular form of protein into the disease-causing isoform. The most likely candidates for this partnership are nucleic acids and glycosaminoglycans. The catalytic effect of RNA or DNA on the PrP C → PrP Sc conversion would depend on the sequence and structure of the nucleic acids and their ability to provide a protective effect. The potential therapeutic use of modified nucleic acids has recently been demonstrated by different groups. In this review, we examined recent research seeking to understand how nucleic acids and GAGs bind to prions, and the resultant implications for cellular toxicity and prion conversion. Figure 6 summarizes possible mechanisms by which a nucleic acid or GAG could affect conversion of the prion protein.
There are, however, many questions that remain to be explored. The nucleic-acid binding properties of the prion protein (both RNA and DNA) might have broader implications for its native function than for disease. The great abundance of RNA in the cytosol that acts in a variety of cellular processes may hint at the physiological target of prion protein. In a recent article, Beaudoin and coworkers (170) described large ribonucleoprotein particles induced by cytoplasmic PrP, which share striking similarities with the chromatoid body. The chromatoid body is an RNA granule that is predicted to function in post-transcriptional gene regulation. Their findings indicate that PrP functions in the assembly and RNA processing center.
The formation of a complex between noninfectious PrP and RNA may be just part of the story. The connection between PrP C , NA, and PrP Sc could be a side effect of the prion protein's native cellular function. The implications of these interactions are causing a paradigm 
